Next Phase Newsletter

Founded in 2018, a healthcare and life sciences focused venture capital firm with USA and China offices manages $600 million USD in total assets, including both USD and RMB funds. The firm has invested in over 50 companies with 10 successful IPO and acquisitions. The firm seeks Series A to Series B opportunities in healthcare and life sciences. Typical check size ranges from $5-15 million USD. The firm prefers to lead, especially for US and China based deals but is open to co-investing. The firm primarily considers companies based in the US and China but is open to opportunities globally.

The firm looks for new opportunities in therapeutics, medical devices, medical services, the diagnostics (IVD) space and healthcare IT. The firm is opportunistic in terms of subsectors and indications. For therapeutics, the firm would like to see some clinical data or safety data.

The firm does not have specific requirements for the management team. Management teams with successful track records would be preferable. The firm will likely seek board seats on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2018 with headquarters in the US closed an initial fund of $20M USD dedicated to early-stage life science ventures from Pre-seed to Seed. The initial size of investment ranges from $250k-1M. The firm partners with companies in the US, Canada, UK, and Israel.

The firm is interested in companies under a $50M valuation cap. The firm acts as a co-investor and will not require board seating.

The firm is interested in deep health-tech. The firm is opportunistic and will consider pre-FDA companies in development and clinical phases. The firm is not interested in traditional pharmaceuticals, diagnostics, or health information technologies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in Canada was co-founded by a physician who previously co-founded a successful private equity firm. The firm is looking to participate in the Seed to Series B financings of early-stage companies with typical investments between USD 0.5 million and USD 5 million. The firm is currently operating out of its second fund. The firm participates in equity investments including SAFEs and convertible notes. The firm invests primarily in companies based in Canada, the United States, Europe, and Israel.

The firm is primarily interested in investing in companies in the digital health sector but will also consider the medical and diagnostic devices sectors that have a digital component to them. The firm is open to all modalities within the digital health but requires that the technologies be patient facing or have a patient component. The firm will not consider investments in biotech or pharma but will consider digital therapeutics. The firm is phase agnostic and will invest in development as well as on the market technologies. The firm will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm is disease agnostic and will consider companies across all indications but prefers that there is ample market size for the technology to be revenue generating.

The firm prefers to work with experienced management teams. The firm looks to invest in companies in which the founder has a significant stake in the business. The firm is an active and strategic investor and will take a board seat as determined by check size on a case-by-case basis. The firm will participate both as a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2018 and is based in the US invests in companies dedicated to working on the intersection of biology, technology, and data science. The firm is focused on early-stage investments from Seed to Series A and also dedicates funds to follow-on investment. Initial check sizes are usually between $1-2M but can fall outside of this range on a case-by-case basis. The firm will consider global opportunities.

The firm invests in the intersection of biology, technology, and data science and the areas of interest fall beyond traditional sectors. The firm is focused on (1) technology driving biology (miniaturization, automation, data sciences); (2) biology as technology (synthetic biology, genetic engineering, stem cells); (3) biology beyond healthcare (agriculture, chemicals/industrials, consumer). The firm will consider cutting edge therapeutics/drug development and platform technologies and diagnostics, is not interested in traditional medical devices or digital health.

The firm focuses on privately owned, early stage companies and is open to working with all types of management teams. The firm likes to step in early and prefers to act as the lead investor, but is open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture arm of a non-profit organization with offices in the US closed an initial fund of $50M USD dedicated to early-stage life science ventures from Series A to C. The initial size of investment ranges from $250k-2M and the firm aims to invest in 10 companies in the upcoming year. The firm prefers to invest in US-based companies but is open to global opportunities.

The firm is niched on four key areas of focus: benign hematology, transfusion medicine, cell therapy, and infectious diseases. The firm will consider therapeutics, diagnostics, and medical devices. The firm will consider therapeutics of all modalities from Pre-Clinical to Phase II. Within diagnostics, the firm is opportunistic and looks at technologies in clinical phases or on the market (must include proof of concept). Within medical devices, the firm is open to all technologies, but is more interested in cell therapy-enabling technologies in clinical phases or on the market (must include proof of concept). Focused on the need for blood-related and cellular technologies, the firm is interested in making not only a financial, but humanitarian investments that also tie back to the parent company.

The firm highly values working with a management team that is 100% committed to the project. The firm prefers that the team has an even distribution of members with scientific and commercial expertise. The firm is a strategic co-investor and seeks to work with the respective knowledge experts on the team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a global company has offices in US and Europe. This fund makes equity investments in early stage companies several industries, including healthcare and life sciences. The firm typically leads or co-leads rounds as a member of a syndicate of investors, and is actively seeking new investment opportunities across all funds.

Within life sciences, the firm is looking for early stage companies working primarily within therapeutics, but is open to other sectors and has made investments in medical devices, diagnostics, and digital health. The firm seeks to invest in areas of strategic interest to its parent company including Immunology (Autoimmune), Oncology, Immuno-oncology, and Fertility. The firm generally looks for companies with novel first-in-class preclinical stage assets as well as novel platform technologies. In addition, the firm is seeking innovation for process, research and/or applied solutions.

The firm is looking for privately held companies with experienced management teams able to take innovative solutions into commercially viable products. The firm looks to take an active role following investing taking a board seat. The firm is able to invest globally.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office based in the US represents approximately 2100 doctors, HNW investors, and angel investors. The firm invests in, but is not limited to, biotechnology, medical devices, and pharmaceuticals. Typical allocation size is $100k-250k per investor, participating in both leading investments and co-investing. The firm invests in companies worldwide, with no specific geographic preferences. Recently, the firm had 3 exits in the life science sector.

The firm is opportunistic in terms of sectors of interest. The firm invests in biotechnology, medical devices, pharmaceuticals, and anything relevant to life sciences that seems to be a good opportunity for the firm. The firm is open to all financial rounds and all stages of development as well as orphan diseases and all indications.

The firm does not have any management team requirements, although depending on the case, taking a board seat may be requested.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.